Today’s post is by Catherine Reed, Global Patient Outcomes and Real World Evidence at the Lilly Research Centre in the UK
With some of the most sophisticated health systems in the world, Europe is a region well-placed to be at the forefront of real world evidence (RWE) in healthcare decision-making.
This means looking at health data in the widest sense, not just understanding a person’s medical history or results from a single clinical trial, but collecting information across dozens of patient cohorts and national databases, for a more informed and well-rounded picture of how to best use RWE to address healthcare challenges.
This could have a very positive impact in Alzheimer’s disease.
We still have many unsolved questions about Alzheimer’s. How can you diagnose an asymptomatic patient? What is the association between a person’s cognitive abilities and their quality of life? What are the long term consequences of interventions? With the help of real world evidence, the entire population becomes the decision-making laboratory.
Lilly has been committed to Alzheimer’s research for nearly 30 years, and we are determined to help the global Alzheimer’s community find a way to prevent this devastating condition. That’s why I’m proud to announce we’ve partnered with leading research organisations as part of a public private partnership in a new Innovative Medicines Initiative project, led by the University of Oxford.
It’s called ROADMAP – Real World Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform. A long name, with quite a long to-do list!
Analysing an unprecedented depth of population and dementia-related data from across multiple Member States including Denmark, France, Netherlands, Spain, Sweden and UK – ROADMAP aims to:
- Lay the foundations for a European-wide RWE platform on Alzheimer’s disease, with guidelines on handling and interpreting dementia-related data
- Identify RWE in Alzheimer’s to better inform the future regulatory environment – for regulators on matters of efficacy and safety and medicines; for medicines manufacturers on building a sustainable payer environment; and for providers on cost-effectiveness
- Provide an approach for stakeholder engagement to better understand the ethical, legal and social implications of RWE in Alzheimer’s
Today, Alzheimer’s disease still has the upper hand. But by bringing together leading researchers across sectors and across Europe, projects like ROADMAP are helping us close in on answers that will ultimately help us address the consequences of this most devastating of diseases.